Abstracts tagged "immunology"

Abstract Number: PP08 • ACR Convergence 2025
Living Well Despite the Challenges of Sjögren’s Disease and Systemic Lupus Erythematous: My Perspective as a Health Care Provider and Patient
Matt Makara, Casey Hogan
Background/Purpose: Typically, the diagnosis of any autoimmune condition can be challenging and take years. In my case, my diagnosis of Sjögren's disesase (SjD) was established…
Abstract Number: 2300 • ACR Convergence 2025
Evaluation of the Ianalumab Treatment Effects on Major Salivary Glands of Patients With Sjögren’s Disease by Multimodal Ultrasound: Results From a Phase 2 Mechanistic Study
sandrine jousse¹, Valerie Devauchelle², baptiste quere¹, Divi Cornec³, Caroline Denis⁴, Thierry MARHADOUR¹, Alice Tison¹, Patricia Baley⁴, Alain SARAUX⁵, Noemi Giglioli⁶, CAROLE SIPS⁶, Shuqi Chen⁷, Rainer Hillenbrand⁶, Richard Siegel⁸, Wolfgang Hueber⁹, Claire Bonal⁶ and Didier Laurent⁶, ¹LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, France, ²UBO, Brest, France, ³LBAI, UMR¹²²⁷, University of Brest, CHU Brest, Brest, France, Brest, Bretagne, France, ⁴CHU Brest, Brest, France, Brest, France, ⁵CHU Brest, Brest, France, ⁶Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland, ⁷China Novartis Institutes for BioMedical Research, Shanghai, China, Shangai, China (People's Republic), ⁸Novartis Biomedical Research, Basel, Switzerland, ⁹Novartis Pharmaceuticals, Basel, Switzerland
Background/Purpose: Ianalumab, a glycoengineered, fully human IgG1 mAb directed against B cell-activating factor (BAFF)-receptor (BAFF-R), targets B cells and their functions through dual mechanism of…
Abstract Number: 1787 • ACR Convergence 2025
Spatial and Quantitative Semiautomated Image Analysis of Synovial Biopsies Studied Using a Novel High-Plex Immunofluorescence Platform
Estefania Quesada-Masachs¹, Luis Peñaranda Bolaño¹, Aakriti Arora², Jessica Murillo-Saich³, Edward Lo⁴, Tad George⁴, Daniel Tanoeihusada⁴, Sara McArdle⁵ and Monica Guma⁶, ¹University of Miami, Miami, FL, ²University of Miami / Jackson Memorial Hospital, Miami, FL, ³University of California, San Diego, San Diego, CA, ⁴RareCyte, Seattle, WA, ⁵La Jolla Institute for Immunology, La Jolla, CA, ⁶University of California San Diego, San Diego, CA
Background/Purpose: Although not part of the formal ACR criteria for RA, PsA, or OA, synovial pathology can be a helpful tool in clinical practice. Histopathologic…
Abstract Number: 1463 • ACR Convergence 2025
Effective Prevention of Psoriatic Arthritis with Secukinumab: A 5-Year Observation from the SERENA Study
Uta Kiltz¹, Petros Sfikakis², Andreas Bounas³, Nicola Gullick⁴, Eric LESPESSAILLES⁵, Jan Brandt-Juergens⁶, Rasho Rashkov⁷, Cynthia Vizcaya⁸, Andreas Clemens⁸, Weibin Bao⁹ and Karl Gaffney¹⁰, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²NKUA - SCHOOL OF MEDICINE, Athens, Greece, ³‘OLYMPION’, General Clinic of Patra, Patra, Greece, ⁴Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, Coventry, United Kingdom, ⁵University Hospital of Orléans, Orleans, France, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Clinic of Rheumatology, University Hospital St. Ivan Rilski, Sofia, Bulgaria, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹⁰Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom
Background/Purpose: Secukinumab, an IL-17A inhibitor, has well-established effectiveness in the treatment of psoriasis (PsO) and psoriatic arthritis (PsA) in both long-term clinical trials and the…
Abstract Number: 1091 • ACR Convergence 2025
Safety Profile of ICIs in Patients with Rheumatoid Arthritis: Results from a Propensity Score-Matched Cohort Study
Betul Ibis¹, Furkan Bahar¹, Yu-Che Lee², Ko-Yun Chang³, Yu Chang⁴ and Cho-Han Chiang⁵, ¹Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, ²University at Buffalo, Buffalo, NY, ³National Jewish Health, Denver, CO, ⁴National Cheng Kung University Hospital, Tainan, Taiwan (Republic of China), ⁵Mount Auburn Hospital, Harvard Medical School, Cambridge
Background/Purpose: Immune-related adverse events (irAEs) are a significant concern for patients receiving immune checkpoint inhibitors (ICIs), particularly those with pre-existing rheumatoid arthritis (RA). Managing ICIs…
Abstract Number: 0905 • ACR Convergence 2025
Development and Characterization of IAR130, a 2+1 Format, CD19 and BCMA Dual Targeting T Cell Engager for Autoimmune Diseases
Jinyang Li, Xiu Han, Yi Wang, Yiyi Li, Zhaoru Ma, Yang Li, Zhimin Zhang, Liu Li, Meng Ni, Jiangkun Bi, Xing Yang, Yao Xiong, Shuaixiang Zhou and Huizhong Xiong, Innovent Biologics (Suzhou) Co., Ltd., Suzhou, Jiangsu, China (People's Republic)
Background/Purpose: Immune reset, achieved through profound and sustained depletion of B cells and/or plasma cells, has demonstrated significant clinical efficacy in patients with severe and…
Abstract Number: 0796 • ACR Convergence 2025
Deciphering Synovial Fluid Immune Dysregulation in Rheumatoid Arthritis through Cytokine Profiling and Single-Cell Transcriptomics
Manon LESTURGIE-TALAREK¹, Francesco Carbone², Virginie Gonzalez³, Adrien Schvartz², Sophie Hecquet⁴, Fiona Oudart⁵, Marion Thomas⁶, Roberto D'Alessandro⁷, Yannick Allanore⁸, Mickael Menager² and Jérôme AVOUAC⁹, ¹Paris University, Paris, France, ²Institut Imagine, Paris, ³INSERMU¹⁰¹⁶, Paris, France, ⁴Cochin Hospital, Paris, France, ⁵APHP - Cochin hospital, Paris, France, ⁶APHP, Paris, France, ⁷Cochin Hospital, Paris, ⁸Université Paris Cité, Paris, France, ⁹Rheumatology department, Cochin hospital, Paris, France
Background/Purpose: Rheumatoid arthritis (RA) is driven by complex inflammatory pathways involving immune cell infiltration into synovial tissue and fluid. Synovial fluid (SF) provides direct insight…
Abstract Number: 0019 • ACR Convergence 2025
Single cell characterization of the circulating immune system in Sjögren’s Syndrome
Alejandro Gómez Gómez¹, Héctor Corominas², Rosario Garcia Vicuña³, Mercedes Freire González⁴, Sheila Melchor-Díaz⁵, Paloma Vela Casasempere⁶, Paula Estrada-Alarcón⁷, Jose Luis Tandaipan⁸, Monica Fernandez Castro⁹, Sara Maria Rojas Herrera¹⁰, Marina Rodríguez López¹¹, Beatriz Paredes-Romero¹², Santiago Muñoz¹³, Marta López¹⁴, Ignacio Braña¹⁵, Gema Bonilla¹⁶, Raúl Menor Almagro¹⁷, Sara Manrique-Arija¹⁸, Mª Angeles Blazquez Cañamero¹⁹, Lilian López-Núñez²⁰, Carles Galisteo Veiga²¹, Juan José Alegre-Sancho²², Jose Rosas Gómez de Salazar²³, Jose Javier Pérez Venegas²⁴, Judit Font-Urgelles²⁵, José Andrés Román Ivorra²⁶, José Miguel Sequí-Sabater²⁷, Rafaela Ortega-Castro²⁸, Clara Moriano²⁹, Guadalupe Manzano-Canabal³⁰, Cilia Peralta-Ginés³¹, Javier Narváez³², Rafael Cáliz-Cáliz³³, Javier Martínez-Ferrin³⁴, Lara Sánchez Bilbao³⁵, Belén Serrano-Benavente³⁶, Natalia Boix- Martí³⁷, Ares Selles-Rius³⁸, Maribel Pérez³⁹, Juan Cañete⁴⁰, Núria Palau Balaña³⁸, Damiana Alvarez Errico³⁹, Yolanda Guillén⁴¹, Juan Ángel Patiño Galindo⁴¹, Antonio Julià¹, Sara Marsal Barril⁴² and Jose Luis Andreu⁴³, ¹Vall d'Hebron Hospital Research Institute, Rheumatology Research Group, Barcelona, Spain, ²Hospital de la Santa Creu i Sant Pau, Rheumatology, Barcelona, Barcelona, Spain, ³Hospital Universitario de la Princesa, Madrid, Spain, ⁴⁴ Hospital Universitario A Coruña, Rheumatology, A Coruña, La coruna, Spain, ⁵Hospital Universitario ¹² de Octubre, Rheumatology, Madrid, Madrid, ⁶Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ⁷Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ⁸Rheumatology. Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain, ⁹PUERTA DE HIERRO HOSPITAL, Madrid, Spain, ¹⁰Hospital de Mérida, Rheumatology, Badajoz, Badajoz, Spain, ¹¹Complejo Hospitalario Universitario de Santiago, Rheumatology, Santiago de Compostela., Santiago de Compostela, Spain, ¹²Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de los Reyes, Spain, ¹³Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁴Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, ¹⁵Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁶Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ¹⁷Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ¹⁸Hospital Regional Universitario Málaga, Malaga, Spain, ¹⁹Hospital Ramon y Cajal, Madrid, Spain, ²⁰Hospital Son Llatzer, Rheumatology, Palma de Mallorca, Palma de Mallorca, Spain, ²¹Hospital Parc Taulí, Rheumatology, Sabadell, Sabadell, Spain, ²²Hospital Universitario Doctor Peset, Valencia, Spain, ²³Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ²⁴Virgen Macarena University Hospital, Sevilla, Spain, Sevilla, Spain, ²⁵Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²⁶Hospital Universitari i Politècnic La Fe, Valencia, Spain, ²⁷Hospital Universitario La Fe (Valencia), Valencia, Spain, ²⁸Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ²⁹Hospital León, LEON, Castilla y Leon, Spain, ³⁰Hospital Virgen de la Concha (Zamora), Zamora, Spain, ³¹Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ³²Hospital Universitario de Bellvitge, Barcelona, Spain, ³³Hospital Universitario Virgen de las Nieves, Rheumatology, Granada, Granada, Spain, ³⁴Hospital Universitario Virgen de la Arrixaca, Rheumatology, Murcia, Murcia, Spain, ³⁵Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ³⁶Hospital Gregorio Marañon, Madrid, Spain, ³⁷Hospital Univetsitari Vall d'Hebron, Rheumatology Department, Barcelona, Spain, ³⁸Rheumatology Research Group, Vall d'Hebron University Hospital, Barcelona, Spain, ³⁹IMIDomics, Barcelona, Barcelona, Spain, ⁴⁰Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ⁴¹IMIDomics, Barcelona, Spain, ⁴²Vall Hebron Hospital Research Institute, Barcelona, Spain, ⁴³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: Sjögren’s syndrome (SS) is a chronic autoimmune disease characterized by the infiltration of circulating immune cells into the salivary and lacrimal glands. The properties…
Abstract Number: 2688 • ACR Convergence 2025
Single cell RNA-seq immune profiling of blood samples from a psoriatic disease clinical trial reveals a CD4 T cell population associated with response to IL-23 blockade
Kathryne Marks¹, Anina Sun², Ifeoluwakiisi Adejoorin¹, Lourdes Perez Chada³, Anna Perillo⁴, Leanne Barrett², Michael Garshick⁵, James Krueger⁶, Joseph Merola⁷, Marcelo DiCarli², Deepak Rao¹ and Brittany Weber⁸, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham And Women's Hospital, Boston, ³Harvard Medical School, Wayland, MA, ⁴The Rockefeller University, New York, NY, USA, New York, NY, ⁵NYU Langone Health, Tenafly, NJ, ⁶Rockefeller University, New York, NY, ⁷UT Southwestern Medical Center, Dallas, TX, ⁸Brigham and Women's Hospital, DEDHAM, MA
Background/Purpose: The use of IL-23 inhibitors (IL-23i) for psoriatic diseases resulted in significant improvement in disease symptoms for many patients. Whether any blood immune cell…
Abstract Number: 2280 • ACR Convergence 2025
Changes of B Cell Subsets During Treatment with Abatacept in Patients with Rheumatoid Arthritis
Athanasios Mavropoulos¹, Christos Liaskos², Ioannis Alexiou³, Christina Katsiari⁴, Dimitrios Bogdanos⁵ and Lazaros Sakkas⁶, ¹University of Thessaly, Volos, Greece, ²University of Thessaly, Faculty of Medicine, Larisa, Greece, ³University General Hospital of larissa, Larissa, Greece, ⁴University General Hospital of Larisa, University of Thessaly Faculty of Medicine, Larisa, Greece, ⁵Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece, ⁶Department of Rheumatology, University of Thessaly, Larissa, Greece
Background/Purpose: Abatacept, an efficacious therapy for rheumatoid arthritis (RA), inhibits the interaction between CD28 on T cells and CD80/CD86 on antigen-presenting cells (APCs). The aim…
Abstract Number: 1777 • ACR Convergence 2025
Granzyme B as a regulator of interferon alpha production in cutaneous lupus erythematosus
Touraj Khosravi¹, Ahmed Eldaboush², Darae Kang³ and Victoria Werth², ¹Department of Dermatology, Perelman Shool of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Potomac, MD
Background/Purpose: Recent studies have shown that monocytes, macrophages, and conventional DCs, but not plasmacytoid dendritic cells (pDC), are major sources of IFNα in cutaneous lupus…
Abstract Number: 1400 • ACR Convergence 2025
Beyond the Glands: Hypogammaglobulinemia as a Clue to Peripheral Neuropathy in Sjogren´s Disease
Renata Fróes Ramos de Lima¹, Regis Sewa Marques², Zoraida Sachetto³ and Alisson Pugliesi⁴, ¹Universidade Estadual de Campinas (UNICAMP), Campinas, Sao Paulo, Brazil, ²Universidade Estadual de Campinas, Campinas, Sao Paulo, Brazil, ³UNIVERSIDADE ESTADUAL DE CAMPINAS, UNICAMP, Campinas, Sao Paulo, Brazil, ⁴Unicamp, Campinas, Brazil
Background/Purpose: Sjogren’s disease (SjD) is a systemic autoimmune disorder characterized by inflammatory involvement of the exocrine glands and extra-glandular manifestations. Among the latter, there is…
Abstract Number: 1090 • ACR Convergence 2025
Quantitative Immunoglobulin Screening Prior to Rituximab Initiation: A Retrospective Cohort Study
Amelia Khoo and Anokhi Saklecha, Yale University, New Haven, CT
Background/Purpose: Rituximab, a monoclonal antibody which binds to the CD20 antigen of B cells, is used in the treatment of many rheumatologic conditions. Due to…
Abstract Number: 0902 • ACR Convergence 2025
A Novel Approach to study ANA+ B Cells in Lupus Integrating Flow Cytometry with Single-Cell culture
Deisy Muriel Velez arteaga¹, Yemil Atisha Fregoso², Hasret Gunduz³ and Betty Diamond⁴, ¹The Elmezzi School of Molecular Medicine, New Rochelle, NY, ²The Feinstein Institute, Long Island, NY, ³The Feinstein Institute, Long Island, ⁴The Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: Studying antinuclear antibody (ANA) producing B cells at the single-cell level offers critical insights into their fine specificity and functional characteristics. However, conventional techniques…
Abstract Number: 0782 • ACR Convergence 2025
Expansion of T-bet⁺ Age-Associated B Cells Is Associated with Clinical Complications in Still’s Disease
Krisztian Csomos¹, Boglarka Ujhazi¹, Mariana Correia Marques², Emily Rosenbaum¹ and Michael Ombrello³, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH, Bethesda, MD, ²Translational Genetics and Genomics Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), North Bethesda, MD
Background/Purpose: Still’s disease is a rare and severe autoinflammatory disorder characterized by daily spiking fevers, arthritis, an evanescent rash, and prominent systemic features, including lymphadenopathy,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].